Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Forecasted to Earn FY2019 Earnings of ($0.70) Per Share

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) – Research analysts at Cantor Fitzgerald issued their FY2019 earnings per share estimates for Aurinia Pharmaceuticals in a research report issued to clients and investors on Thursday, October 17th. Cantor Fitzgerald analyst A. Young expects that the biotechnology company will earn ($0.70) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. Cantor Fitzgerald also issued estimates for Aurinia Pharmaceuticals’ FY2020 earnings at ($0.97) EPS.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.02). Aurinia Pharmaceuticals had a negative return on equity of 50.08% and a negative net margin of 13,231.97%. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.05 million.

AUPH has been the topic of a number of other research reports. Zacks Investment Research lowered shares of Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 16th. BidaskClub lowered shares of Aurinia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, October 3rd. Bloom Burton restated a “buy” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, October 2nd. ValuEngine lowered shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 10th. Finally, Citigroup started coverage on shares of Aurinia Pharmaceuticals in a research note on Monday, September 9th. They set an “outperform” rating and a $14.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. Aurinia Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $15.18.

Shares of NASDAQ AUPH opened at $4.88 on Monday. Aurinia Pharmaceuticals has a 1 year low of $3.52 and a 1 year high of $7.85. The firm’s 50 day moving average price is $5.43 and its 200 day moving average price is $6.06. The firm has a market cap of $451.63 million, a P/E ratio of -6.42 and a beta of 1.11.

A number of large investors have recently bought and sold shares of AUPH. Vivo Capital LLC raised its stake in Aurinia Pharmaceuticals by 57.7% during the second quarter. Vivo Capital LLC now owns 1,913,623 shares of the biotechnology company’s stock worth $12,592,000 after purchasing an additional 700,333 shares during the period. Orbimed Advisors LLC raised its stake in Aurinia Pharmaceuticals by 12.1% during the second quarter. Orbimed Advisors LLC now owns 3,531,002 shares of the biotechnology company’s stock worth $23,234,000 after purchasing an additional 381,192 shares during the period. BlackRock Inc. raised its stake in Aurinia Pharmaceuticals by 3.1% during the second quarter. BlackRock Inc. now owns 921,425 shares of the biotechnology company’s stock worth $6,063,000 after purchasing an additional 28,129 shares during the period. Wells Fargo & Company MN raised its stake in Aurinia Pharmaceuticals by 35.5% during the second quarter. Wells Fargo & Company MN now owns 77,993 shares of the biotechnology company’s stock worth $513,000 after purchasing an additional 20,432 shares during the period. Finally, Point72 Asset Management L.P. raised its stake in Aurinia Pharmaceuticals by 670.2% during the second quarter. Point72 Asset Management L.P. now owns 22,083 shares of the biotechnology company’s stock worth $145,000 after purchasing an additional 19,216 shares during the period. 31.12% of the stock is currently owned by institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Featured Article: What does an outperform rating mean?

Earnings History and Estimates for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.